Advanced Medicine In China’s Post

📬Article of the Week📜 Suggested by the #BPDCN International Registry❗️-Astghik Voskanyan 🖍 #Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia primarily affecting older men, with involvement often in the skin, bone marrow, lymph nodes, and #CNS. Due to its rarity and unique management needs, patients should ideally be referred to specialized cancer centers with clinical trials and expertise in BPDCN. Comprehensive staging and expert hematopathology review are essential. BPDCN universally expresses #CD123, the IL-3 receptor, a key therapeutic target. Treatment options include tagraxofusp, a CD123-targeting IL3-diphtheria toxin conjugate, or conventional chemotherapy. Allogeneic #HSCT in first remission (CR1) is recommended if feasible. Treatment choice depends on disease features, patient health, goals, and available center expertise. Close monitoring for toxicities, especially capillary leak syndrome (CLS), is crucial when using tagraxofusp, particularly in the first cycle. 🔖Authors:Marlise Luskin ,Andrew Lane, MD, PhD 📜 https://lnkd.in/dsjNx6X3 #Tagraxofusp, #cancer, #immuneoncology, #HSCT

Did you know that Lymphoma Cancer is prevalent among young adults? If you notice symptoms like swollen lymph nodes, unexplained weight loss, persistent fatigue, or night sweats, don't delay seeking medical advice. At Dharan Cancer Specialty Centre, we provide advanced care through state-of-the-art technology and evidence-based practices to ensure optimal treatment. Our cutting-edge CT, MRI, X-ray, and Biopsy services enable early diagnosis, and we offer tailored options such as Chemotherapy and Immunotherapy. Your well-being is our priority. With compassionate support, we empower you to confidently navigate your Lymphoma journey. Together, we can overcome Lymphoma Cancer and aspire to a brighter, healthier future. #lymphoma #chemotherapy #lymphomacancer #lymphomaawareness #cancerpatients #cancercare #cancercentre #ComprehensiveCancerCare #besthospital #besttreatment #lymphomaawareness #besthospital #radiationtherapy #dharancancercare #lymphomacancertreatment #swollenglands #persistentfatique #ctscan #mri For Further Query #Call: +91 - 99439 39990 #Visit: https://lnkd.in/fqCzSnA

Multiple myeloma, often simply referred to as myeloma, is a type of cancer that affects plasma cells, a type of white blood cell found in the bone marrow. In myeloma, abnormal plasma cells multiply uncontrollably, crowding out healthy blood cells in the bone marrow and interfering with the production of normal blood cells. This can lead to anemia, weakened bones, and a compromised immune system. Some common symptoms of myeloma include bone pain (especially in the back and ribs), weakness, fatigue, recurrent infections, unexplained weight loss, and kidney problems. However, in the early stages, myeloma may not cause any noticeable symptoms, making it challenging to diagnose. Treatment for myeloma typically involves a combination of therapies, including chemotherapy, targeted therapy, immunotherapy, and stem cell transplant, depending on the stage and severity of the disease. While myeloma is considered incurable, advances in treatment have significantly improved outcomes and quality of life for many patients. #CancerAwarness #Cancerprevention #cancer #cancerFax

**Patient Story | Chinese CAR-T Therapy: An Inspiring Journey of Changing Fate for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)** #CART #DLBCL #Lymphoma #CARTtherapy #RRDLBCL #Patientstory #CD19 China has made significant progress in CAR-T therapy for cancer, particularly in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). **Mr. Wang's Journey with CAR-T Therapy** Mr. Wang, a 45-year-old R/R DLBCL patient, faced relapse after standard R-CHOP chemotherapy and another failed regimen. Near despair, he connected with the Advanced Medicine In China team, where he was introduced to CAR-T therapy at a top hospital. **The CAR-T Treatment Process** Under expert care, Mr. Wang's T cells were modified to target his lymphoma. After infusion, the team closely monitored him, managing side effects like fever and fatigue. **Positive Results and Remission** Within a month, Mr. Wang’s condition improved significantly. By the sixth month, he achieved complete remission, showcasing the efficacy of China's CAR-T expertise. **Hope for the Future** Mr. Wang's success story is one of many, illustrating the potential of Chinese CAR-T therapy to offer new hope for those facing cancer worldwide. ����To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation! WhatsApp: Https://wa.me/+8613717959070 Email: doctor.huang@globecancer.com #CancerTreatment #RRLymphoma #ChineseMedicalAdvances #Immunotherapy #PatientSuccess #Oncology #HopeForCancer #MedicalBreakthrough #CancerResearch #China

NEW PUBLICATION IN EUROPEAN JOURNAL OF CANCERS The #liver is the most frequent site of #metastases in #colorectal #cancer (CRC). This study aimed to assess the response rate and survival outcomes in metastatic CRC patients with non-liver metastases (NLM) compared to those with liver metastases (LM) across different lines of treatment. A total of 17,924 mCRC patients included in 26 trials from the ARCAD CRC database were analyzed.  This study reported that liver metastases are generally a poor prognostic factor, particularly in later lines of treatment for mCRC patients, except when anti-EGFR therapy is used in the first and second lines. It also justifies using liver metastases as a stratification factor in future clinical trials for mCRC. #LivermetastaticColorectalCancer #Prognosticvalue #Chemotherapy #TargetedTherapy Morteza Raeisi Benoist Chibaudel Thierry André Qian Shi Takayuki Yoshino Chiara Cremolini Digestive Cancers Europe

🌟 Unlocking the Mysteries of High-Risk Mantle Cell Lymphoma! 🌟 Understanding high-risk mantle cell lymphoma (MCL) has reached new heights! Thanks to significant advancements in recognizing the molecular origins and resistance mechanisms, we're gaining a clearer picture of this complex disease. MCL patients face unique challenges, especially when identified with high-risk factors. From aggressive histologies to the intricate dance of molecular aberrations like a dysregulated cyclin D1 and an aberrant SOX11-CD70 axis, there is much to navigate. These indicators not only help in diagnosis but also guide treatment plans. As treatments evolve, including innovative cellular therapies, staying informed about the diseases’ physiology and progression is more critical than ever. This knowledge paves the way for groundbreaking bi- and tri-specific T-cell therapies and next-generation clinical trials. 🚀 Dive into the future of MCL care. Explore comprehensive updates on recognizing high-risk factors and managing MCL with forward-thinking strategies in this enlightening article! Read Research 👉🏻 https://lnkd.in/dyEtrbgE #research #pubmed

Hi everyone Primary intestinal lymphoma are about 10% of all colonic malignancies. It can be classified into two principal categories: Follicular B cell lymphomas and Intestinal T cell lymphomas. We reported a rare case of 30 years old patient who was admitted to our hospital with abdominal pain in the lower part of abdomen since 2 months associated with tenderness &. weight loss. CT examination revealed nodal mass at ileo-colic artery with a diameter of 37 mm and along with villous adenomas involving all circumferential diameters. The histological investigation showed a lymphoplasmacytic and eosinophilic infiltration with CD20, CD10, bcl2, bcl6 positive CD3, CD5, cyclin D1 negative. Based on above findings the diagnosis of follicular B cell lymphoma was made. Karyotyping and fish analysis was done and it shows 50,XY,del(1)(q32q42),q23),(q31),add(3)(p21),(q23),+8,+12,(14)(q13),+20. #rare #case #follicular #lymphoma #gi #tractt #disorders #chemoradiation #lymphoproliferative #neoplasms #chromosomal #defects

Tertiary Lymphoid Structures (TLSs) and Tumor Infiltrating Lymphocytes (TILs) - Prognostic Significance

Prognostic Significance of Tertiary Lymphoid Structures and Tumour-Infiltrating Lymphocytes in Clear Cell Renal Carcinoma A study investigated the characteristics and clinical significance of tertiary lymphoid structures (TLSs) and tumour-infiltrating lymphocytes (TILs) in clear cell renal cell carcinoma (ccRCC) across 1,286 patients. TLSs were present in 16% of tumours and associated with improved survival and therapy response, particularly when mature and dense. Conversely, high infiltration of scattered TILs predicted poor prognosis. The study highlighted the importance of immune infiltration patterns, showing that mature TLSs correlate with decreased relapse and death risks, whereas high TILs indicate worse outcomes, revealing complex immune dynamics in ccRCC. The link to the original article is in the comments. If you found this post valuable, give it a like and share it with your network! 😃 #CancerResearch #Immunotherapy #RenalCellCarcinoma #TertiaryLymphoidStructures #TumorInfiltratingLymphocytes #TLSs #TILs #ImmunoOncology Be at the forefront of cancer immunotherapy breakthroughs! 🔬 Subscribe for FREE to my monthly Newsletter for a dose of knowledge and the latest advancements: https://lnkd.in/ec5sV-iP  📧 #ImmunotherapyFrontiers #StayInformed #ImmunotherapyExploration #DontMissOut"

Here are some of the highlights of my State of the art talk on #Endoscopic #cancer #ablation at the American Society for Gastrointestinal Endoscopy (ASGE) learning center last week at Digestive Disease Week® (DDW) Cancer ablation is still in its infancy and has a lot of potential. Areas that are well established today include #pancreatic #neuroendocrine #cancer and #cryotherapy for #esophagealcancer. Areas of future interest include #pancreaticcancer and low #rectal cancer The drivers include: •Fast paced technological innovation in #medicine and #endoscopy •Desire for #organpreservation and more focus on quality of life •Advancement in #cancer treatment making systemic therapy more effective •Possible #genomic difference between the metastasis and the primary #gastrointestinal cancers •Interest in manipulating the #tumor #microenvironment and antitumor #immune response